MLH1 and triple-negative breast carcinoma: Treatment of CT26, MC38, mouse triple-negative breast cancer 4T1, and mouse pancreatic cancer Pan18 with LB100 induced MLH1 loss and an increase in MSI status (Supplementary Fig. 7).